Belimumab Onset of Action — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

EasyRheumatology PharmacologyBelimumab Onset of ActionSCE Rheumatology

A 40-year-old woman with active autoantibody-positive systemic lupus erythematosus has started belimumab as add-on therapy. According to current NICE guidance, after what duration should response be assessed to determine whether belimumab may be continued, with continuation requiring a reduction in SELENA-SLEDAI score of at least 4 points?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — 24 weeks

The correct answer is 24 weeks. NICE TA752 permits continuation of belimumab beyond 24 weeks only when the SELENA-SLEDAI score has improved by at least 4 points. This is consistent with the current SmPC, which advises continuous assessment and consideration of discontinuation when disease control has not improved after 6 months. Eight weeks is too early for the formal UK continuation decision. Although efficacy outcomes have been reported at 52 weeks and longer follow-up points, these are not the NICE-mandated assessment point. The original wording about “maximal response” was imprecise: belimumab has no single established time at which maximal clinical effect is reached, and improvement may continue beyond 24 weeks.

Reference: NICE. Belimumab for treating active autoantibody-positive systemic lupus erythematosus, TA752, recommendation 1.1, 2021. https://www.nice.org.uk/guidance/ta752/chapter/1-Recommendations